TXMD vs. CORT

In the year-to-date period, TXMD achieves a -51.33% return, which is significantly lower than CORT's 56.71% return. Over the past 10 years, TXMD has underperformed CORT with an annualized return of -41.00%, while CORT has yielded a comparatively higher 32.64% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for TherapeuticsMD, Inc. (TXMD) and Corcept Therapeutics Incorporated (CORT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current TXMD Sharpe Ratio is -1.23, which is lower than the CORT Sharpe Ratio of 1.11. The chart below compares the historical Sharpe Ratios of TXMD and CORT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither TXMD nor CORT has paid dividends to shareholders.

The maximum TXMD drawdown since its inception was -99.99%, which is greater than CORT's maximum drawdown of -94.28%. Use the drawdown chart below to compare losses from any high point for TXMD and CORT. For additional features, visit the drawdowns tool.

TherapeuticsMD, Inc. (TXMD) and Corcept Therapeutics Incorporated (CORT) have volatilities of 11.70% and 11.44%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between TherapeuticsMD, Inc. and Corcept Therapeutics Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.